413results about "Polypeptide with fusion toxin" patented technology

The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.

Methods for producing a protective immune response to Porcine Epidemic Diarrhea Virus (PEDV) is provided wherein a fusion protein comprising the S1 Spike protein of the virus operably fused to the heat labile enterotoxin B subunit (LTB) peptide is expressed in a plant and the plant or plant product comprising the fusion protein is orally administered to an animal. The vaccine can be produced by introducing into a plant a construct comprising a promoter preferentially directing expression to seed of said plant, a nucleic acid encoding the S1-LTB fusion protein and a nucleic acid targeting expression to the endoplasmic reticulum of the plant. When orally administered to an animal, a protective response is observed, including a serum antibody response and mucosal immune response.

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

The present invention relates to receptor tyrosine kinase-like orphan receptor 1 (ROR1) specific antigen binding molecules and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).

The present invention refers to: a) at least one peptide recognizing tumor endothelial cell markers, the peptide being preferably: —an αv-integrin ligand, preferably a ligand of αvβ3, βvβ5, αvβ8, α5β1 and / or αvβ6 integrin, more preferably the peptide includes a sequence having a RGD motif or of a CgA sequence or—a ligand of CD 13 receptor, more preferably the ligand includes a sequence having a NGR motif or functional fragments or derivatives or a biologically active variant thereof and b) saporin or functional fragments, derivatives or a biologically active variant thereof.

Bioconjugates are described comprising alpha-fetoprotein (AFP) linked with a cytotoxin through a disulfide, glutathione-sensitive linker, for cancer treatment. In a preferred embodiment, the bioconjugate is an AFP variant linked with a maytansinoid cytotoxin via the glutathione-sensitive linker so that the bioconjugate comprises either specific high or low ratio of cytotoxins per AFP.

Provided is a fusion protein, which can be produced at a low cost, in a short period, and with a high yield. Also provided are a coding nucleic acid of the fusion protein, an in-vitro synthesis system, a preparation method, and the like. The fusion protein has: an effector moiety A for killing a target cell, including a toxin molecule; a targeting vector moiety B that binds to a target site on the target cell, the targeting vector moiety being derived from an antibody or a cytokine; and a first linker L1 for linking the effector moiety A to the targeting vector moiety B, wherein the first linker L1 comprises at least 3 amino acid residues. Preferably, the linking mode of the effector moiety A, the first linker L1, and the targeting vector moiety B from the N-terminus to the C-terminus is A-L1-B or B-L1-A.

The invention discloses a matrix metalloproteinase-responsive multifunctional bionic ferritin nano material as well as a preparation method and application thereof. The method comprises the following steps: modifying melittin on the surface of a ferritin nanoparticle through a genetic engineering method, connecting by using a linker containing a matrix metalloproteinase 9 (MMP-2 / 9) restriction enzyme cutting site, expressing the obtained recombinant ferritin (SEQ ID NO: 6) in escherichia coli, and self-assembling to form the enzyme response functionalized bionic nanoparticle. According to the method, melittin can be connected to ferritin nanoparticles in series, the toxicity of melittin is remarkably reduced, and the melittin responds to matrix metalloproteinase in a tumor microenvironment so as to kill tumor cells; meanwhile, intravenous administration of melittin can be realized, and the melittin injection has a good treatment effect on in-situ and metastatic tumors.

Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. In certain embodiments, the anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. In certain embodiments, the one or more additional antigen comprises Programmed cell death ligand 1 (PDL1).

The present invention is directed to the vegetative insecticidal proteins (Vips) modified to comprise heterologous bacterial carbohydrate binding modules and the methods of use thereof. Expression of modified proteins resulted in variations to activity against lepidopteran pest species of agricultural importance such as Corn earworm and Fall armyworm conveying broad spectrum insect control.

New insecticidal proteins, nucleotides, peptides, their expression in plants, methods of producing the peptides, new processes, production techniques, new peptides, new formulations, and new organisms, a process which increases the insecticidal peptide production yield from yeast expression systems. The present invention is also related and discloses selected endotoxins we call cysteine rich insecticidal peptides (CRIPS) which are peptides derived from Bacillus thuringiensis (Bt) and their genes and endotoxins in combination with toxic peptides known as Inhibitor Cystine Knot (ICK) genes and peptides as well as with other types of insecticidal peptides such as trypsin modulating oostatic factor (TMOF) peptide sequences used in various formulations and combinations; of both genes and peptides, useful for the control of insects.

The invention belongs to the field of gene engineering, and provides a mycoplasma ovipneumoniae multi-epitope fusion protein and preparation and application thereof.The inventor firstly successfully predicts antigen epitopes of three virulence genes and performs tandem expression on the predicated antigen epitopes to prepare a fusion protein antigen, and the fusion protein antigen is used for preparing the mycoplasma ovipneumoniae multi-epitope fusion protein. A secondary structure, a tertiary structure, physicochemical properties (including hydrophilicity, stability, PI value and the like), antigenicity, sensitization and the like of the fusion protein are predicted through biological online software, and the success rate of a test is increased; meanwhile, the fusion protein connected in series with the three virulence genes of the mycoplasma ovipneumoniae is prepared into a subunit vaccine, and a good immune protection effect is also achieved. The recombinant mycoplasma ovipneumoniae multi-epitope fusion protein prokaryotic expression plasmid pET28a < + >-EHP is successfully constructed, tandem expression of mycoplasma ovipneumoniae on an escherichia coli prokaryotic system is achieved, and an expression product can obtain a good immune protection effect.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

The present disclosure relates to compositions and methods for treating disease. More particularly, the present disclosure relates to stable chimeric synthetic proteins and their use in treating cancer.

To provide methods for treating cancer of subjects in need thereof, methods for inhibiting cancer progression, methods for preventing cancer metastasis, and methods for delivering therapeutic compounds to the brain.SOLUTION: Disclosed herein are: a drug delivery molecule comprising a ligand that targets a cell surface molecule, a transmembrane domain and a payload-binding domain; and a pharmaceutical composition comprising the drug delivery molecule. Also disclosed is a method comprising: identifying a subject in need thereof, providing a composition comprising the drug delivery molecule and administering to the subject an effective amount of the composition.SELECTED DRAWING: Figure 1

Disclosed are fusion proteins that can be manufactured at low cost, in a short cycle, and in high yield. The coding nucleic acid, in vitro synthesis system, and method for manufacturing the fusion protein are also disclosed. The fusion protein is used to kill target cells and comprises an effector portion A containing a toxin molecule, a guide vector portion B that binds to a target of the target cell and is derived from an antibody or cytokine, and a first linker L1 that links the effector portion A and the guide vector portion B, wherein the first linker L1 comprises at least three amino acid residues; preferably, the effector portion A, the first linker L1, and the guide vector portion B are linked from the N-terminus to the C-terminus in the A-L1-B or B-L1-LA direction.

Provided herein is a hypervesiculating Escherichia coli Nissle (ΔECHy) bacterium engineered to produce outer membrane vesicles (OMVs), said OMVs packaging a fusion peptide including cytolysin A (ClyA) and hyaluronidase (Hy). Also provided are methods of remodeling a tumor, methods of treating cancer, and pharmaceutical compositions including the engineered ΔECHy bacterium.

The present invention discloses a multifunctional biomimetic ferritin nanomaterial responsive to matrix metalloproteinases and its preparation method and application. The present invention modifies melittin on the surface of ferritin nanoparticles by a genetic engineering method, connects with a linker containing a matrix metalloproteinase 9 (MMP‑2 / 9) cleavage site, and obtains recombinant ferritin (SEQ ID NO: 6) expressed in Escherichia coli and self-assembled to form enzyme-responsive functionalized biomimetic nanoparticles. The present invention utilizes this method to connect melittin in series on ferritin nanoparticles, significantly reducing the toxicity of melittin, and responding to matrix metalloproteinases in the tumor microenvironment to kill tumor cells; At the same time, intravenous administration of melittin can also be achieved, with good therapeutic effects on both in situ and metastatic tumors.

The present invention provides methods for treating an inflammatory condition of the eye in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-1R ligand, or portion or variant thereof, and a disease-modifying agent.

An IgG1 Fc monomer, a preparation method therefor and an application thereof. Causing an Fc dimer of a novel IgG1 Fc monomer sequence for which an antibody IgG1 constant region is modified to become an Fc monomer by means of the modification on a human antibody IgG1 constant region Fc that uses antibody engineering technology, and maintaining an FcRn binding function; the present application has the feature of very low non-specific binding with unrelated proteins, and the main features of the Fc monomer comprise the T366, L368, P395, and K409 positions in a CH3 region of the constant region of the antibody having mutations, and the monomer being highly efficiently expressed in prokaryotic cells; the monomer may bind to FcRn by using a pH-dependent specific binding mode, and has the feature of very low non-specific binding. By using said Fc monomer, the same may be fused or coupled with various proteins, polypeptides, small molecules, nucleic acids and the like for different targets such that the fused or coupled molecules have the feature of being capable of binding to FcRn by using pH dependence.

The present invention refers to a process for obtaining antigen-presenting vesicles (APV) that enables the coupling of one or more antigens, wherein such APV comprises (i) an outer membrane vesicle of gram-negative bacteria (OMV); (ii) at least one antigenic protein or peptide; and (iii) at least a pair of molecules with complementary affinities comprising a first affinity molecule that associates with the vesicle, and a complementary affinity molecule that associates with the protein or peptide. Thus, the process for obtaining the APV of the present invention is essential to achieve a form of presentation that consists of a vesicle that makes it possible to attach one or more proteins, or a plurality of different protein or peptide antigens. In that regard, such process comprises the following steps: (a) conjugating the first affinity molecule to the vesicle (OMV); (b) obtaining the antigen protein(s) or peptide(s) in fusion with the complementary affinity molecule; and (c) coupling the fusion protein obtained in step "b" with the product obtained in step "a".

A platform for therapy provides a multi-target therapeutic molecule comprising an anti-CD3 antigen binding fragment of an anti-CD3 antibody linked with a linker to one or more auto-antigen(s). The molecule can be further linked by another linker linking either an anti-CD3 antigen binding fragment of an anti-CD3 antibody or an auto-antigen to an anti-CD19 or anti-CD20 antibody or antigen-binding fragment thereof. The auto-antigens include Dsg1, Dsg3, bullous pemphigoid antigen 180, bullous pemphigoid antigen 230, MuSK, anti-phospholipase A2 Receptor, Factor VIII, one or more protein expressed by a viral vector administered to a subject for gene therapy, a DNA molecule carried by a gene therapy viral vector. A pharmaceutical composition comprises a disclosed multi-target therapeutic molecule is disclosed. Methods of treating diseases using the disclosed molecules are disclosed.

Immunogenic fusion proteins against infectious animal diseases. A fusion protein is disclosed, which comprises a CD40-binding domain; an antigen of a pathogen; a translocation domain located between the CD40-binding domain and the antigen, and a furin and / or cathepsin L cleavage site located between the CD40-binding domain and the translocation domain. Also disclosed are pharmaceutical compositions, expression vectors and use of the fusion proteins of the invention for eliciting an antigen-specific cell-mediated immune response, or for reducing, inhibiting, treating and / or ameliorating an infectious animal disease caused by a pathogen in an animal in need thereof

The target protein expression vector of the present invention includes a polynucleotide encoding a viral nucleocapsid as a fusion partner of the target protein. Also, the target protein production method of the present invention includes the steps of: constructing a target protein expression vector including a target protein and a polynucleotide encoding a viral nucleocapsid as a fusion partner of the target protein; introducing the target protein expression vector into a host cell to produce a transformant; and culturing the transformant.

The present invention relates to fusion proteins for use in the induction of immune responses and in the treatment of cancer, and in particular as immunopotentiators and for use in the induction of humoral immune responses and cell-mediated immune responses.